{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T16:55:23Z","timestamp":1795107323848,"version":"4.10.3"},"reference-count":31,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T00:00:00Z","timestamp":1634256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diseases"],"abstract":"<jats:p>Fabry disease (FD) is a genetic disease included in the group of lysosomal storage disorders, caused by X-linked deficiency of the enzyme alpha-galactosidase A. The aim of this study was to evaluate different aspects related to the quality of life (QoL) of a multicentre cohort of Italian patients with FD. An observational survey was conducted to measure health-related quality of life (HR-QoL) in FD patients using the CAPI (Computer-Assisted Personal Interview) method: 106 patients (mostly women) responded to the questionnaire. Geographically, 53.7% of patients lived in northern Italy, 18.9% in central Italy and 27.4% in southern Italy or the Islands. All data were collected through a five-dimensional EuroQoL questionnaire referring to functional aspects (mobility, personal care, routine activities) and perception of physical\/mental well-being (pain or discomfort, anxiety or depression). A descriptive analysis of responses was performed; FD patients were compared in terms of QoL with subjects suffering from other chronic diseases, such as Crohn\u2019s disease, chronic hepatitis, cirrhosis and multiple sclerosis. Difficulty in normal daily activities was reported by 47.2% of FD patients. About one third of subjects also had mobility difficulties. Feelings of loneliness and isolation were reported by 33.3% of those being 60\u201369 years old. Anxiety was equally reported in both oldest and youngest patients (66.7%), while depression, relational problems, fear of other people\u2019s judgement increased along with age, reaching 66.7% in the over-70-years group. Male patients were largely troubled about the risk of physical disability, particularly those aged 60 years or over. Furthermore, FD patients had a poorer QoL than people suffering from other chronic inflammatory disorders. Our study upholds that FD patients have a poor QoL, as already known, negatively impacting psychic well-being and social activities. Our survey has also found a worse QoL in FD patients compared with other severe chronic disorders.<\/jats:p>","DOI":"10.3390\/diseases9040072","type":"journal-article","created":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T13:59:52Z","timestamp":1634565592000},"page":"72","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Survey about the Quality of Life of Italian Patients with Fabry Disease"],"prefix":"10.3390","volume":"9","author":[{"given":"Barbara","family":"Polistena","sequence":"first","affiliation":[{"name":"Department of Economic and Finance, University of Rome Tor Vergata, C.R.E.A. Sanit\u00e0, via Columbia n. 2, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"Rigante","sequence":"additional","affiliation":[{"name":"Department of Life Sciences and Global Health, Fondazione Policlinico A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico Luca","family":"Sicignano","sequence":"additional","affiliation":[{"name":"Rare diseases and Periodic Fever Research Center, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Verrecchia","sequence":"additional","affiliation":[{"name":"Rare diseases and Periodic Fever Research Center, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaele","family":"Manna","sequence":"additional","affiliation":[{"name":"Rare diseases and Periodic Fever Research Center, Department of Internal Medicine, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"d\u2019Angela","sequence":"additional","affiliation":[{"name":"Department of Economic and Finance, University of Rome Tor Vergata, C.R.E.A. Sanit\u00e0, via Columbia n. 2, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-2850","authenticated-orcid":false,"given":"Federico","family":"Spandonaro","sequence":"additional","affiliation":[{"name":"Department of Economic and Finance, University of Rome Tor Vergata, C.R.E.A. Sanit\u00e0, via Columbia n. 2, 00133 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: Guidelines for the evaluation and management of multi-organ involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13023-015-0296-8","article-title":"Quality of life in patients with Fabry disease: A systematic review of the literature","volume":"10","author":"Arends","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1023\/A:1015511908710","article-title":"Quality of life of patients with Fabry disease","volume":"11","author":"Gold","year":"2002","journal-title":"Qual. Life Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6014","DOI":"10.2174\/13816128113199990387","article-title":"Neurological complications of Anderson-Fabry disease","volume":"19","author":"Tuttolomondo","year":"2013","journal-title":"Curr. Pharm. Des."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/8904_2017_21","article-title":"Treatment of depression in adults with Fabry disease","volume":"38","author":"Ali","year":"2018","journal-title":"JIMD Rep."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s13023-020-1307-y","article-title":"Depressive symptoms in Fabry disease: The importance of coping, subjective health perception and pain","volume":"15","author":"Geurtsen","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s10545-013-9643-x","article-title":"Cognitive dysfunction and depression in Fabry disease: A systematic review","volume":"37","author":"Bolsover","year":"2014","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lelieveld, I.M., B\u00f6ttcher, A., Hennermann, J.B., Beck, M., and Fellgiebel, A. (2015). Eight-year follow-up of neuropsychiatric symptoms and brain structural changes in Fabry disease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137603"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s10545-007-0708-6","article-title":"Depression in adults with Fabry disease: A common and under-diagnosed problem","volume":"30","author":"Cole","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/GIM.0b013e31802d8321","article-title":"Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life","volume":"9","author":"Wang","year":"2007","journal-title":"Genet. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/arclin\/acu047","article-title":"Cognitive and psychological functioning in Fabry disease","volume":"29","author":"Sigmundsdottir","year":"2014","journal-title":"Arch. Clin. Neuropsychol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jval.2013.04.008","article-title":"Italian population-based values of EQ-5D health states","volume":"16","author":"Scalone","year":"2013","journal-title":"Value Health"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: A measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e000025","DOI":"10.1136\/bmjgast-2014-000025","article-title":"The societal burden of chronic liver diseases: Results from the COME study","volume":"2","author":"Scalone","year":"2015","journal-title":"BMJ Open Gastroenterol."},{"key":"ref_16","unstructured":"Dolan, P., Gudex, C., Kind, P., and Williams, A. (2021, October 09). A Social Tariff for EuroQol: Results from a UK General Population Survey\u2014Discussion Paper 138. Available online: https:\/\/www.york.ac.uk\/che\/pdf\/DP138.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1136\/jmg.2004.025791","article-title":"Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: Data from FOS (Fabry Outcome Survey)","volume":"42","author":"Hoffmann","year":"2005","journal-title":"J. Med. Genet."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.2147\/CEOR.S98226","article-title":"A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample","volume":"8","author":"Mozzi","year":"2016","journal-title":"Clinicoecon. Outcomes Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1177\/1352458517708176","article-title":"New insights into the burden and costs of multiple sclerosis in Europe: Results for Italy","volume":"23","author":"Battaglia","year":"2017","journal-title":"Mult. Scler."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hec.1608","article-title":"Patient-reported outcome measures in the NHS: New methods for analysing and reporting EQ-5D data","volume":"19","author":"Devlin","year":"2010","journal-title":"Health Econ."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Drummond, M.F., Sculpher, M.J., Torrance, G.W., O\u2019Brien, B.J., and Stoddart, G.L. (2005). Methods for the Economic Evaluation of Health Care Programme, Oxford University Press. [3rd ed.].","DOI":"10.1093\/oso\/9780198529446.001.0001"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hays, R.D., and Reeve, B.B. (2008). Measurement and Modeling of Health-Related Quality of Life, San Diego Academic Press.","DOI":"10.1016\/B978-012373960-5.00336-1"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1083\/jcb.201208152","article-title":"The cell biology of disease: Lysosomal storage disorders: The cellular impact of lysosomal dysfunction","volume":"199","author":"Platt","year":"2012","journal-title":"J. Cell Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s10354-010-0841-y","article-title":"An overview on bone manifestations in Gaucher disease","volume":"160","author":"Mikosch","year":"2010","journal-title":"Wien Med. Wochenschr."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000064674","article-title":"Cardiac structural involvement in mucopolysaccharidoses","volume":"98","author":"Rigante","year":"2002","journal-title":"Cardiology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13023-020-01368-x","article-title":"Assessing the impact of the five senses on quality of life in mucopolysaccharidoses","volume":"15","author":"Giugliani","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1477-7525-10-116","article-title":"Measuring patient experiences in Fabry disease: Validation of the Fabry-specific Pediatric Health and Pain Questionnaire (FPHPQ)","volume":"10","author":"Ramaswami","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"ref_28","first-page":"31","article-title":"Long-term outcomes with agalsidase alfa enzyme replacement therapy: Analysis using deconstructed composite events","volume":"14","author":"Beck","year":"2017","journal-title":"Mol. Genet. Metab. Rep."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1023\/B:BOLI.0000005658.14563.77","article-title":"Enzyme replacement therapy in heterozygous females with Fabry disease: Results of a phase IIIB study","volume":"26","author":"Kampmann","year":"2003","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1002\/hep.27010","article-title":"Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C","volume":"59","author":"Petta","year":"2014","journal-title":"Hepatology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10072-011-0499-2","article-title":"Multiple sclerosis in Italy: Cost-of-illness study","volume":"32","author":"Patti","year":"2011","journal-title":"Neurol. Sci."}],"container-title":["Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/4\/72\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:15:19Z","timestamp":1760166919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-9721\/9\/4\/72"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,15]]},"references-count":31,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["diseases9040072"],"URL":"https:\/\/doi.org\/10.3390\/diseases9040072","relation":{},"ISSN":["2079-9721"],"issn-type":[{"value":"2079-9721","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,15]]}}}